Skip to main content

Exicure Announces Board and Committee Changes

Written by Customer Service on . Posted in Public Companies.

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced changes to its Board of Directors and Board committees following actions approved by the Company’s Board of Directors at its special meeting held on June 24, 2026.

The Company’s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.

The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham’s resignation. In addition, the Board approved an increase in the size of the Board from five to six directors and appointed Eui Seok Han as a Class III director to fill the newly created directorship. Both appointments are effective June 30, 2026.

Following a review of the applicable Nasdaq independence standards, the Board determined that Eui Seok Han qualifies as an independent director under the Nasdaq Listing Rules. Following these changes, the Company continues to satisfy the Nasdaq requirement that a majority of its Board consist of independent directors.

The Board also confirmed the composition of its Audit Committee, which will continue to consist of Yoon Tae Han (Chair), Dongho Lee and Gyeong Seog Cheon. In addition, the Board established a Compensation Committee comprised of Eui Seok Han (Chair) and Dongho Lee, effective June 30, 2026.

Additional information regarding these matters will be included in the Company’s Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s corporate governance, Board composition and strategic direction. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Media Contact

Exicure, Inc.

pr@exicuretx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.